Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Radioimmunotherapy (RIT) with α-emitting radionuclides is an attractive approach for the treatment of minimal residual disease because the short path lengths and high energies of α-particles produce optimal cytotoxicity at small target sites while minimizing damage to surrounding normal tissues. Pre...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Park, Steven I., Shenoi, Jaideep, Pagel, John M., Hamlin, Don K., Wilbur, D. Scott, Orgun, Nural, Kenoyer, Aimee L., Frayo, Shani, Axtman, Amanda, Bäck, Tom, Lin, Yukang, Fisher, Darrell R., Gopal, Ajay K., Green, Damian J., Press, Oliver W.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2010
Sujets:
Lymphoid Neoplasia
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC2993626/
https://ncbi.nlm.nih.gov/pubmed/20702781
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-05-282327
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires